<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010031</url>
  </required_header>
  <id_info>
    <org_study_id>21-310</org_study_id>
    <nct_id>NCT05010031</nct_id>
  </id_info>
  <brief_title>A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change</brief_title>
  <official_title>Phase II Study to Examine Precision Radiation in Patients With Pathogenic Mutations in ATM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether reduced-dose radiotherapy is an effective treatment for&#xD;
      metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of&#xD;
      radiation that would still be effective to treat these tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, phase II noninferiority, prospective trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure rate of irradiated lesion</measure>
    <time_frame>6 month</time_frame>
    <description>Defined as (i) radiographic progression or (ii) re-irradiation to the treated site. If PET is performed, radiographic criteria will be evaluated per PERCIST</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive reduced dose radiation to radiographically progressive lesions identified on imaging (including asymptomatic bone metastases).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Palliative radiotherapy</intervention_name>
    <description>The first cohort of 26 evaluable patients will be treated with 4Gyx2, followed by a 6 month observation period post-RT to assess for treatment failures. If 7 or more failures are observed, cohort 1 will be closed and 4Gyx3 will be explored in the second cohort. If at most 6 failures are detected in the first cohort, dose will be further reduced to 4Gyx1 for the second cohort. Radiation therapy will be delivered according to department standards, including normal tissue constraints per hypofractionated guidelines. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.</description>
    <arm_group_label>radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignancy with at least one metastatic lesion referred for&#xD;
             palliative radiotherapy&#xD;
&#xD;
          -  Pathogenic mutation in ATM (somatic and germline allowed)&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Age â‰¥ 18 years.&#xD;
&#xD;
          -  Able to provide informed consent.&#xD;
&#xD;
          -  Patients at reproductive potential must agree to practice an effective contraceptive&#xD;
             method during radiation treatments.&#xD;
&#xD;
          -  Expected life expectancy of at least 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radiotherapy to the intended treatment site that precludes developing a&#xD;
             treatment plan that respects normal tissue tolerances.&#xD;
&#xD;
          -  Serious medical co-morbidities precluding radiotherapy.&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Concomitant pathogenic mutation in p53&#xD;
&#xD;
          -  Lesions excluded from de-escalation include regions in which the risk of local disease&#xD;
             progression is unacceptably high, including CNS disease and cord compression, and&#xD;
             areas in which re-irradiation would not be feasible, including spinal cord overlap.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Xu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Xu, MD, PhD</last_name>
    <phone>646-888-6863</phone>
    <email>xua@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Gomez, MD</last_name>
    <phone>212-639-2087</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (All Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Xu, MD, PhD</last_name>
      <phone>646-888-6863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (All protocol activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Xu, MD, PhD</last_name>
      <phone>646-888-6863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (All protocol activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Xu, MD, PhD</last_name>
      <phone>646-888-6863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (All protocol activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Xu, MD, PhD</last_name>
      <phone>646-888-6863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (All Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Xu, MD, PhD</last_name>
      <phone>646-888-6863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Xu, MD, PhD</last_name>
      <phone>646-888-6863</phone>
    </contact>
    <contact_backup>
      <last_name>Daniel Gomez, MD</last_name>
      <phone>212-639-2087</phone>
    </contact_backup>
    <investigator>
      <last_name>Amy Xu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (All protocol activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Xu, MD, PhD</last_name>
      <phone>646-888-6863</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reduced-dose Radiation</keyword>
  <keyword>Pathogenic Mutations</keyword>
  <keyword>ATM (ataxia telangiectasia mutated)</keyword>
  <keyword>21-310</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

